Gemcitabine-based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second-line treatment(s) established yet. Aberrant activation of the MAPK pathway in patients with BTC indicates its importance in BTC.
| INTRODUCTION
Biliary tract cancer (BTC) is a highly fatal malignancy that arises from the epithelial lining of the gallbladder and bile ducts. It encompasses intrahepatic, perihilar, and extrahepatic cholangiocarcinoma as well as carcinomas arising from the gallbladder, and is characterized by regional lymph node metastasis, vascular encasement, and distant metastasis. 1 Biliary tract cancer is the sixth leading cause of cancerrelated deaths in Japan. 2 The prognosis of BTC is poor because most patients present at advanced stages and are thus diagnosed with unresectable tumors. 3, 4 The standard first-line treatment for locally advanced or metastatic BTC is systemic chemotherapy with cisplatin and gemcitabine. 3, 5, 6 The alternative regimen with tegafur (S-1), an oral fluoropyrimidine, has shown a comparable response rate (RR) as that with gemcitabine. 7, 8 Moreover, S-1 has been investigated as a second-line treatment for patients with advanced BTC refractory to gemcitabine. 9, 10 Molecular targeted agents, such as cetuximab, erlotinib, or sorafenib alone or in combination with chemotherapy have not shown promising results in small Phase Ib and Phase II trials.
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Owing to the limited benefits of these treatments, there are no standard second-line treatments established for patients with BTC; this highlights the need for a new drug or chemotherapy regimens as a second-line treatment option. 12 Increasing evidence indicates that RAS and RAF proto-oncogenes are mutated and are thus activated at a significant rate in BTC; this highlights the importance of the RAS/RAF/MEK/ERK (MAPK) pathway in the pathogenesis of this disease. [13] [14] [15] [16] So far, two MEK inhibitors, selumetinib and MEK162 (ARRY-438162), have demonstrated promising results as monotherapy in patients with unresectable, locally advanced, or metastatic BTC. 17, 18 Trametinib, another MEK inhibitor, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity. 19 Preclinical data indicate inhibited cell growth in BTC models with KRASmutated cell lines after treatment with trametinib. 20 Therefore, based on the importance of the MAPK pathway in biliary carcinogenesis and potential activity shown by MEK inhibitor in the treatment of BTC, trametinib was investigated as a potential novel single agent treatment for unresectable BTC.
The present phase IIa study was undertaken to investigate the preliminary efficacy and safety of an oral MEK inhibitor, trametinib, in patients with advanced BTC refractory to a gemcitabine-based regimen. The protocol and amendments were reviewed and approved by the local independent ethics committees of the participating institutions.
| MATERIALS AND METHODS

| Patients
The study was carried out in accordance with Good Clinical Practice and ethical principles of the Declaration of Helsinki. All patients provided written informed consent to participate in the study. This study is registered with ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT01943864).
| Study design
This was a phase IIa, open-label, single-arm, multicenter study carried out at five centers in Japan. The study comprised a 21-day screening phase, followed by a treatment phase and a follow-up phase. All patients were randomized to receive oral trametinib 2 mg once daily and were required to visit the site every 4 weeks (treatment phase).
Patients received trametinib until disease progression, death, or an unacceptable AE. Tumor response was evaluated every 8 weeks. All patients who permanently discontinued the study treatment without disease progression were followed up for progression until initiation of new anticancer therapy, disease progression, or death. All patients who permanently discontinued the study treatment were followed up for survival and new anticancer therapy every 8 weeks until death or until the patient had been followed up for 1 year from study initiation (day 1), whichever was earlier.
| Concomitant medication
Supportive care therapies, including blood transfusion, treatment with antibiotics, antiemetics, antidiarrheal medications, and analgesics, were permitted during the study as clinically indicated. Other anticancer therapies (e.g., radiation therapy, surgery, and/or tumor embolization) and use of other investigational drugs were prohibited within 28 days (or five half-lives, whichever was shorter) preceding the first dose of trametinib and during the study.
| Study objectives
The primary objective of the study was to determine the 12-week non-PD rate, defined as the proportion of patients without progression at week 12, as assessed by RECIST 1.1.
Secondary objectives of the study were to assess the safety profile of trametinib and to determine PFS, OS, and overall RR in the overall population. Potential of blood-or tumor tissue-derived biomarkers to predict biological activity and sensitivity or resistance to trametinib treatment were evaluated as exploratory end-points of the study. 
| Statistical analysis
The study was designed as a single-arm trial to evaluate the clinical utility of trametinib monotherapy compared with historical singleagent data for S-1, a second-line therapy, and selumetinib, used both as first-and second-line therapy. 9, 18 Considering the median PFS with S-1 and selumetinib was 10.8 and 16.1 weeks, respectively, in the reference study, 10,18 the null hypothesis for threshold and the alternative hypothesis for expected non-PD rate at week 12 were specified as 25% and 60%, respectively. Based on the null hypothesis and to achieve power >90%, 20 subjects were to be enrolled in the study. Exact binomial 90% and 95% CIs were computed for non-PD rate, and one-sided P-value of the exact binomial test to reject the null hypothesis (≤25%) was provided at a one-sided 5% level of significance. Progression-free survival was summarized using KaplanMeier curves. The 1-year OS was estimated using the Kaplan-Meier curves of OS. For overall RR, the exact 95% CI for RR was calculated. The duration of response was summarized for patients with confirmed complete response or partial response (PR). Primary assessments were based on imaging data. Investigator assessments were considered as primary assessments, whereas independent reviewer assessments were considered supplementary. All treated patients were included in the safety evaluations. (Table 1) .
| Efficacy results
The non-PD rate at week 12 was 10% (90% CI, 1. Figure S1 ; Table 2 ). The primary end-point did not reach the threshold rate of 25%. The one-sided P-value of exact binomial test to reject the null hypothesis was above the prespecified significance level of 0.05 (P = .976).
Progression or death was reported in 18 (90%) and 16 (80%) patients per investigator and independent radiologist assessment, respectively, and the corresponding median PFS was estimated as OS was estimated to be 20.0% (95% CI, 6.2-39.3). The investigatorassessed best response was SD in 13 patients (65%) and PD in seven patients (35%), whereas the independent radiologist-assessed best response was PR in one patient (5%) and SD in 10 patients (50%;
T A B L E 2 Non-progressive disease rate at week 12 in phase IIa study of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine (all treated patients)
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12 (60) 11 (55) Censored before week 12, a n (%)
3 (15) 4 (20) Non-PD rate -, Not applicable; CI, confidence interval; CR, complete response; PD, progressive disease; PR, partial response; RR, response rate; SD, stable disease. Table 3 ). Maximum reduction in tumor size compared to baseline was observed in seven patients per investigator assessment and in six patients per independent radiologist assessment ( Figure 2 ).
Most patients discontinued the study treatment within 12 weeks owing to disease progression ( Figure 3 ). Three patients showed longer PFS over 12 weeks, particularly, one patient showed PR at week 13 and had confirmed PR at week 21. This patient continued on the study treatment for approximately 120 weeks, and the time to response was 20.1 weeks.
| Safety results
All patients experienced at least one AE ( 
| Targeted exome sequencing
Owing to tumor biopsy quality, targeted exome sequencing was possible for only nine subjects. A total of eight variants from three subjects were identified and validated as somatic (Table 5) ; of these, six occurred uniquely in the exceptional responder, including a synonymous NF1 exon 12 splice variant and a loss-of-function variant in ARID1A.
| DISCUSSION
To date, the combination of gemcitabine and cisplatin has been the only first-line palliative treatment for advanced BTC with no clear second-line therapy options. 3, 5 The present study is the first proofof-concept study evaluating the clinical activity of trametinib in patients with advanced BTC refractory to gemcitabine. As there is no established second-line treatment for BTC, the present study was designed as a single-arm study to evaluate the clinical utility of trametinib compared with historical single-agent data for S-1 and selumetinib. The median PFS with S-1 and selumetinib based on the reference studies was 10.8 and 16.1 weeks, respectively, whereas the 12-week non-PD rate was estimated to be 25% and 60%, respectively. The primary analysis was carried out to determine whether the non-PD rate at week 12 was greater than or equal to the threshold rate (25%). In this study, investigator-assessed non-PD rate at week 12 was 10% (P = .976), which means the primary endpoint was not met. The investigator-assessed median PFS was estimated to be 10.6 weeks. Three patients in this study had longer PFS (>12 weeks), one of whom showed PR at week 13, which was con- short median PFS. 26 In an open-label, single-arm study, combination therapy with oral vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib and trametinib, reported modest clinical activity with signs of possible cumulative toxicity in patients with advanced cholangiocarcinoma. The study did not achieve statistically significant improvement in 4-month PFS over the prespecified null hypothesized 4-month PFS (P = .063). 27 Although the aforementioned phase II trials present some scientific evidence, adequately powered trials are needed to identify the most suitable regimen and patient population who may benefit from such treatment.
Genomic profiling studies of BTC have reported a highly diverse collection of underlying mutations with a relatively low overall mutational burden in individual patients, the exception being a small cohort whose tumors are hypermutated due to errors in DNA mismatch repair. [28] [29] [30] [31] [32] The results of the targeted exome sequencing in our clinical cohort are consistent with those findings, with six of nine patients failing to show any somatic mutations in our panel of genes and two of the remaining patients, in which somatic variants were validated, harboring alterations in DNA mismatch repair genes (Table 5) . Missense variants were observed in RAF1, MSH6, NOTCH2, and PIK3CB, with one patient showing a frameshift variant in ARID1A. Variants in all of these genes have been observed previously in BTC in larger cohorts, the most prevalent being in ARID1A
with a mutation frequency of 10%-20%. [28] [29] [30] Although no KRAS or TP53 variants were identified in our clinical samples, the cohort size was small and such negative findings likely reflect the lack of dominant oncogenic drivers in this disease. 29 The long PFS observed in one patient was notable in two respects. First, six of the eight validated somatic mutations across the nine-patient cohort were in this patient, which suggests that the patient's carcinoma may be hypermutated. Although the patient hosted a synonymous variant in the mismatch repair endonuclease, PMS2, this variant is also present in the healthy population (rs12532895) and hypermutation cannot be verified within our dataset. The result, however, is intriguing because MEK inhibition has recently been shown to protect against T-cell apoptosis driven by chronic antigen stimulation 33 and such a mechanism is expected to be especially relevant in hypermutated tumors with a higher incidence of antigenic epitopes. Given that immunotherapy has reported benefit in patients with BTC42 and that the above mechanism appears to work in parallel to the programmed cell death 1 35 If a similar functional dependence could be disclosed in BTC, this could potentially explain the exceptional response to trametinib observed in this patient ( Figure S1 ). Other somatic variants, a frameshift loss-offunction mutation in ARID1A, which may be expected to increase activation of the PI3K/AKT pathway, 36 and missense mutations in NOTCH2 and PIK3CB, have no known link to MEK inhibition sensitivity.
A limitation of this study was that patients were enrolled regardless of their mutation status. Furthermore, the small number of enrolled patients, inclusion of subtypes of BTC, and inclusion of mixed patients receiving second-and third-line treatment, may have contributed to the lack of efficacy observed in this trial. Biliary tract cancer is reported to have varied biological behavior and sensitivity to chemotherapies among primary tumor types. Moreover, differences in terms of prior treatment regimens and/or number of prior regimens administered may affect treatment sensitivity of chemotherapy as well as PFS/OS. Further investigation is required to study the relationship between efficacy and the aforementioned factors. 37 In conclusion, the primary end-point of this study, non-PD rate at week 12, did not reach statistical significance. Although the primary end-point was not met, prolonged PFS was observed in one patient. The overall safety profile was comparable to that of trametinib monotherapy to date. Given the limited number of biopsies evaluable by next-generation sequencing, the significance of the PIK3CB, NOTCH2, ARID1A, and NF1 mutations identified in the subject with a PR is not known; however, efforts to understand the role of these mutations and sensitivity to trametinib or other targeted therapies in BTC are warranted. 
